Comparison between Olanzapine- Aprepitant- Granisetron on nausea and vomiting
- Conditions
- ausea and Vomiting.Nausea and vomiting
- Registration Number
- IRCT20190217042735N1
- Lead Sponsor
- Zahedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 105
Informed consent
Receiving chemotherapy regimens with moderate and high nausea and vomiting
Serum Creatinine 2 or less
AST and ALT less than 3 times of normal upper limit
Absolute Neutrophil counts of more than 1500 cubic millimeters
Not having another cause for nausea and vomiting, such as brain tumors and stomach cancer
Having nausea and vomiting too much and uncontrollable
Having allergies or showing other side effects of medications
Pregnant and lactating women
Having chronic illnesses such as: severe heart failure, uncontrolled diabetes, cardiac arrhythmia and cardiac infarction over the past 6 months
Use of other interventions or confusing drugs (Quinolones, abdominal radiotherapy, other underlying conditions, etc.)
Treatment with other antipsychotic drugs (Risperidone, Quetiapine, Clozapine, Phenothiazine) 30 days before entering the study
Having known problem in the CNS (cerebral metastasis or seizure) or cognitive impairment
Having nausea and vomiting 24 hours before treatment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ausea and vomiting. Timepoint: First day and 48 to 72 hours after chemotherapy. Method of measurement: The patients will be monitored for nausea and vomiting on the first day and 48 to 72 hours after chemotherapy, and their clinical data will be recorded by the information form.
- Secondary Outcome Measures
Name Time Method